Key Takeaways
- Shares of EYPT plummeted to a 52-week low of $4.06, declining more than 71% on August 17, 2026
- DURAVYU failed to achieve its primary visual acuity endpoint in the Phase 3 LUGANO study’s complete dataset
- A post-hoc analysis that excluded an atypical patient subset demonstrated non-inferiority compared to aflibercept
- Secondary endpoints delivered favorable results, showing a 42% decrease in treatment frequency versus aflibercept
- The company maintains plans to submit regulatory filings in H1 2027, contingent on forthcoming LUCIA trial outcomes
Shares of EyePoint Pharmaceuticals (EYPT) experienced a devastating collapse of over 71% on August 17, 2026, plunging to a 52-week low of $4.06 following the disclosure of topline data from the company’s crucial Phase 3 LUGANO clinical study.
EyePoint Pharmaceuticals, Inc., EYPT
The clinical trial evaluated DURAVYU 2.7 mg in individuals suffering from wet age-related macular degeneration. The investigational treatment fell short of achieving its primary visual acuity endpoint based on the complete patient population analysis.
This was the critical information that triggered the immediate market reaction, resulting in a rapid and severe sell-off.
EyePoint attempted to provide additional perspective on the results. A post-hoc evaluation that removed a limited group of patients whose vision deterioration stemmed from causes other than wet AMD demonstrated that DURAVYU achieved non-inferiority when compared to on-label aflibercept. However, post-hoc evaluations hold substantially less regulatory credibility than pre-determined primary endpoints, and market participants factored this limitation into their trading decisions immediately.
The secondary outcomes presented a notably positive narrative. DURAVYU achieved a 42% reduction in treatment frequency when benchmarked against aflibercept. Study participants demonstrated impressive supplement-free intervals extending through Week 56, exhibited robust anatomic disease control, and the therapy maintained a favorable safety profile across multiple dosing cycles.
Breaking Down the Clinical Results
The investigational drug didn’t experience complete failure. It missed achieving the pre-specified primary endpoint in the full population analysis, which represents the critical regulatory threshold, but the comprehensive data profile appears more nuanced than the sharp stock decline would indicate.
EyePoint is now directing attention toward LUCIA, its second confirmatory Phase 3 clinical trial, with topline results anticipated in late 2026. The company continues to target a U.S. regulatory submission during the first half of 2027, although this timeline now hinges significantly on the outcomes LUCIA produces.
The organization is simultaneously advancing Phase 3 development programs in diabetic macular edema, ensuring continued pipeline activity beyond the wet AMD therapeutic area.
Wall Street Price Targets Remain Significantly Above Trading Levels
Prior to the clinical data release, Mizuho had elevated its price objective for EYPT to $39, reaffirming an Outperform recommendation. Stifel had launched coverage with a Buy recommendation and established a $40 price objective.
The latest analyst recommendation on file shows a Buy rating with a $39 price objective. This represents substantial potential appreciation from current trading levels, although these targets were established before today’s data disclosure and will likely undergo revisions.
EYPT exhibits a beta coefficient of 1.74, illustrating the considerable volatility characteristic of this equity. Prior to today’s decline, the stock had gained 33% during the preceding 12-month period, demonstrating the dramatic impact binary clinical events can have on biotechnology valuations.
Shareholders recently voted to approve modifications to EyePoint’s 2023 Long-Term Incentive Plan, authorizing an additional 4.9 million shares. Board members including Gƶran Ando, M.D. and Jay S. Duker, M.D. secured election at the 2026 Annual Meeting for terms extending through 2027.
EyePoint’s market capitalization currently stands at roughly $1.27 billion. Management has indicated the company maintains sufficient cash reserves to fund operations through Q4 2027.
Topline results from the LUCIA Phase 3 trial are projected for late 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
